- Zacks•2 hours ago
Regeneron (REGN) and partner Sanofi's atopic dermatitis treatment, dupilumab, is under priority review in the U.S. A response should be out by Mar 29, 2017.
- Investor's Business Daily•58 minutes ago
The FDA could approve a breakthrough adult eczema treatment from Regeneron and Sanofi as soon as March.
- Reuters•4 hours ago
Sanofi SA said on Monday the U.S. Department of Health and Human Services (HHS) approved $43.18 million in funding to accelerate the development of a Zika vaccine, as efforts to prevent the infection gather momentum. The funding from the HHS' Biomedical Advanced Research and Development Authority (BARDA) will be used for mid-stage trials, expected to begin in the first half of 2018, and for manufacturing, the French drugmaker said. Work on the vaccine began in March as a collaborative effort between the U.S. Department Of Defense's Walter Reed Army Institute of Research (WRAIR), BARDA and the National Institutes of Health.
NYSE - NYSE Real Time Price. Currency in USD
|Bid||38.07 x 2500|
|Ask||38.08 x 900|
|Day's Range||37.92 - 38.15|
|52wk Range||37.41 - 51.88|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||21.22|
|Avg Vol (3m)||2,454,938|
|Dividend & Yield||1.66 (4.34%)|